As the most potent professional antigen presenting cells, dendritic cells (DCs) have the
ability to activate both naive CD4 and CD8 T cells. Recognized for their exceptional ability to …

Multiple myeloma (MM) is a hematological malignancy characterized by clonal proliferation
of plasma cells. Although therapeutic advances have been made to improve clinical …

Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable
development over recent decades. However, this field is currently in a state of flux toward …

The main obstacle of multiple myeloma (MM) therapy is the compromised immune
microenvironment, which leads to MM relapses and extramedullary disease progression. In …

Cancer immunotherapy, which harnesses the immune system to fight cancer, has begun to
make a breakthrough in clinical applications. Dendritic cells (DCs) are the bridge linking …

Prostate cancer is the most commonly diagnosed cancer in men worldwide, making up 21%
of all cancer cases. With 345,000 deaths per year owing to the disease, there is an urgent …

Gliomas account for the majority of brain malignant tumors. As the most malignant subtype of
glioma, glioblastoma (GBM) is barely effectively treated by traditional therapies (surgery …

Cancer therapeutic vaccine can induce antigen-specific immune response, which has
shown great potential in cancer immunotherapy. As the key factor of vaccine, antigen plays a …

Background The long-term effectiveness of immunotherapies against Multiple Myeloma
(MM) remains elusive, demonstrated by the inevitable relapse in patients. This underscores …

Simple Summary Multiple myeloma (MM) is the second-most common blood cancer and is
currently incurable despite recent advances in treatment. The immune cells which are …